These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1746070)

  • 1. [First national Enantone Symposium. Progress in therapy of prostatic cancer. Multicenter study: long-term follow-up].
    Fornara P
    Urologe A; 1991 May; 30(3 Suppl):10-2. PubMed ID: 1746070
    [No Abstract]   [Full Text] [Related]  

  • 2. [Galenic innovation: Enantone monthly depot preparations].
    Hübner R
    Urologe A; 1991 May; 30(3 Suppl):7-8. PubMed ID: 1746074
    [No Abstract]   [Full Text] [Related]  

  • 3. [Hormone kinetics in suppression with monthly Enantone depot preparations].
    Schilling A
    Urologe A; 1991 May; 30(3 Suppl):9. PubMed ID: 1746075
    [No Abstract]   [Full Text] [Related]  

  • 4. [Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma].
    DeAntoni E; Crawford ED
    Urologe A; 1995 Sep; 34(5):382-8. PubMed ID: 7483154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Advanced prostatic carcinoma--which hormone therapy when?].
    Studer UE
    Urologe A; 1995 Sep; 34(5):361-6. PubMed ID: 7483151
    [No Abstract]   [Full Text] [Related]  

  • 6. Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival.
    Bournakis E; Efstathiou E; Varkaris A; Wen S; Chrisofos M; Deliveliotis C; Alamanis C; Anastasiou I; Constantinides C; Bamias A; Dimopoulos MA
    Anticancer Res; 2011 Apr; 31(4):1475-82. PubMed ID: 21508406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
    Cox MC; Scripture CD; Figg WD
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [LHRH analogs as monthly depot preparations in treatment of advanced prostate cancer].
    Urologe A; 1991 May; 30(3 Suppl):2-3. PubMed ID: 1746071
    [No Abstract]   [Full Text] [Related]  

  • 9. [Renaissance of estrogen therapy in advanced prostate carcinoma?].
    Smith PH; Robinson MR
    Urologe A; 1995 Sep; 34(5):393-7. PubMed ID: 7483156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of metastatic prostatic cancer with monthly injections of leuprolide acetate depot].
    Jiménez Cruz JF; Vera Donoso CD; Iborra I; Solsona E; Forner E; Villavicencio H; Díaz C; González C; Rioja L; Pertusa C
    Actas Urol Esp; 1994 Feb; 18(2):90-3. PubMed ID: 7976707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer: metastatic.
    Michaelson D; Talcott J; Smith M
    Clin Evid; 2002 Jun; (7):804-11. PubMed ID: 12230706
    [No Abstract]   [Full Text] [Related]  

  • 12. [Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status].
    Stege R; Carlström K; Hedlund PO; Pousette A; von Schoultz B; Henriksson P
    Urologe A; 1995 Sep; 34(5):398-403. PubMed ID: 7483157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Results of long-term follow-up in treatment of endometriosis with the GnRH agonist leuprorelin acetate depot (Enantone-Gyn monthly depot)].
    Regidor PA; Schindler AE; Bühler K; Gerhard I; Kimmig R; Meinen K; Hoffmann G; Lübben G; Kienle E
    Zentralbl Gynakol; 1996; 118(5):283-90. PubMed ID: 8701625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
    Pollack A; Horwitz EM
    Nat Clin Pract Oncol; 2005 Jan; 2(1):12-3. PubMed ID: 16264846
    [No Abstract]   [Full Text] [Related]  

  • 16. [Theoretical considerations and initial clinical results of intermittent hormone treatment of patients with advanced prostatic carcinoma].
    Bruchovsky N; Goldenberg SL; Rennie PS; Gleave M
    Urologe A; 1995 Sep; 34(5):389-92. PubMed ID: 7483155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
    Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer: improving the therapeutic index.
    Scher HI
    Semin Oncol; 1994 Oct; 21(5):688-93. PubMed ID: 7524157
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LHRH ethylamide against prostatic cancer].
    Yamanaka H; Makino T; Kumasaka F; Shida K
    Hinyokika Kiyo; 1984 Apr; 30(4):545-60. PubMed ID: 6435416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
    Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.